Agilent Technologies (A) PT Lowered to $82.00

Agilent Technologies (NYSE:A) had its price objective reduced by Bank of America from $88.00 to $82.00 in a research report sent to investors on Wednesday morning, BenzingaRatingsTable reports. Bank of America currently has a buy rating on the medical research company’s stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Agilent Technologies from a hold rating to a buy rating and set a $79.00 price target on the stock in a research report on Monday, January 21st. Deutsche Bank boosted their price target on shares of Agilent Technologies from $80.00 to $85.00 and gave the company a buy rating in a research note on Tuesday, February 12th. Robert W. Baird reaffirmed a buy rating and set a $82.00 target price (up from $77.00) on shares of Agilent Technologies in a research note on Wednesday, February 20th. JPMorgan Chase & Co. upped their target price on shares of Agilent Technologies to $85.00 and gave the stock an overweight rating in a research note on Thursday, February 21st. Finally, Barclays upped their target price on shares of Agilent Technologies from $80.00 to $83.00 and gave the stock an overweight rating in a research note on Thursday, February 21st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Agilent Technologies has a consensus rating of Buy and an average target price of $86.58.

Shares of NYSE A traded down $7.08 during trading on Wednesday, hitting $68.93. The company had a trading volume of 2,136,393 shares, compared to its average volume of 2,031,359. Agilent Technologies has a fifty-two week low of $60.42 and a fifty-two week high of $82.27. The firm has a market cap of $23.45 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.33. The company has a quick ratio of 2.79, a current ratio of 3.39 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.01). Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the business earned $0.65 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Equities research analysts anticipate that Agilent Technologies will post 3.06 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

In other news, CEO Michael R. Mcmullen sold 8,746 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $77.67, for a total value of $679,301.82. Following the completion of the transaction, the chief executive officer now owns 447,684 shares in the company, valued at approximately $34,771,616.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Paul N. Clark sold 2,823 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $80.31, for a total transaction of $226,715.13. Following the completion of the transaction, the director now owns 88,857 shares of the company’s stock, valued at approximately $7,136,105.67. The disclosure for this sale can be found here. Insiders have sold a total of 57,329 shares of company stock valued at $4,535,225 in the last quarter.

Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc grew its position in shares of Agilent Technologies by 8.8% in the third quarter. Legal & General Group Plc now owns 1,712,847 shares of the medical research company’s stock valued at $120,832,000 after purchasing an additional 138,944 shares during the period. Vanguard Group Inc boosted its position in Agilent Technologies by 0.8% during the third quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock worth $1,703,929,000 after acquiring an additional 194,607 shares during the last quarter. Federated Investors Inc. PA boosted its position in Agilent Technologies by 32.9% during the third quarter. Federated Investors Inc. PA now owns 463,930 shares of the medical research company’s stock worth $32,726,000 after acquiring an additional 114,733 shares during the last quarter. Sit Investment Associates Inc. boosted its position in Agilent Technologies by 218.8% during the fourth quarter. Sit Investment Associates Inc. now owns 3,825 shares of the medical research company’s stock worth $258,000 after acquiring an additional 2,625 shares during the last quarter. Finally, Gateway Investment Advisers LLC boosted its position in Agilent Technologies by 12.8% during the fourth quarter. Gateway Investment Advisers LLC now owns 15,760 shares of the medical research company’s stock worth $1,063,000 after acquiring an additional 1,791 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Recommended Story: 12b-1 Fees

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.